In the near future, medical professionals across the United States could soon be equipped with two strategies to safeguard the youngest members of society against RSV.
On August 22, the U.S. Food and Drug Administration granted approval for the inaugural RSV vaccine tailored for pregnant individuals. This novel approach involves vaccinating expectant mothers between the 32nd and 36th weeks of pregnancy, allowing the vaccine-induced immune defenses to be passed on to newborns, affording protection during their initial months of life (SN: 4/27/23).
RSV, short for respiratory syncytial virus, induces respiratory tract ailments and stands as the primary cause of hospital admissions among infants in the U.S. Annually, this virus lands an estimated 58,000 to 80,000 children below the age of 5 in hospital care. This newly endorsed vaccine accompanies the recently sanctioned antibody treatment Beyfortus (nirsevimab), offering an additional preventive avenue against the virus.
Dr. Betsy Herold, a specialist in pediatric infectious diseases and virology, expresses enthusiasm, noting, “It’s great that we have new tools to protect kids.”
In a trial encompassing around 7,000 pregnant individuals, fewer newborns born to those who received the Pfizer-manufactured vaccine exhibited severe symptoms in comparison to infants whose parents received a placebo.
While these outcomes hold promise, the integration of the new vaccine and antibody drug into healthcare practices nationwide remains uncertain. Dr. Herold, hailing from Albert Einstein College of Medicine and the Children’s Hospital at Montefiore in New York City, highlights that although the FDA grants approval for drugs and vaccines, the U.S. Centers for Disease Control and Prevention (CDC) furnishes recommendations on their usage.
On August 3, the CDC proposed that all infants under 8 months receive a dose of Beyfortus, with those aged 8 to 19 months at high risk for severe RSV also being candidates for the dose.
In the near future, the CDC will likely deliberate on whether pregnant individuals should avail themselves of the new vaccine and potentially how it could be incorporated alongside the antibody drug.
As the nation’s arsenal against RSV evolves, advisors to the CDC will likely consider two pivotal factors when determining whether and how to integrate the vaccine into the RSV prevention toolkit.
